Coeheal
All articlesCancer Research

Fenbendazole & Cancer: A Deep Dive into the Evidence

13 min readMay 25, 2026By M. Santos

The dog dewormer that sparked a global cancer treatment movement. A thorough examination of the preclinical evidence, the case reports, and the unanswered questions.

Evidence qualityPreclinical interest — no human clinical trial evidence

Fenbendazole shows antiproliferative activity in cell and animal studies. No randomised controlled trials have established efficacy or safety as a cancer treatment in humans.

For educational purposes only — not medical advice. How we evaluate evidence →

Part 4 of 8Integrative Cancer Protocols Series

A deep dive into alternative and integrative cancer treatment approaches.

Unproven cancer treatment

Fenbendazole is a veterinary antiparasitic drug. It has shown antiproliferative activity in cell and animal studies, but no randomised controlled trials have established its efficacy or safety as a cancer treatment in humans.

This article reviews the preclinical research and the biological mechanisms being investigated — not a treatment protocol.

Always consult a qualified physician or oncologist before making any changes to your treatment plan. This article is for informational purposes only and does not constitute medical advice, a diagnosis, or a treatment recommendation.

Written by

M. Santos

Health science researcher and medical writer

Reviewed by

Dr. A. Ferreira, MD

General practitioner with integrative medicine training. Reviewed for factual accuracy and safety information. Fenbendazole is not an approved cancer treatment; this article covers preclinical research only.

Last reviewed

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Our editorial standards →

Fenbendazole (methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate) is a broad-spectrum anthelmintic — a drug that kills parasitic worms — used extensively in veterinary medicine for dogs, cats, and livestock. It belongs to the benzimidazole class of drugs, which includes mebendazole (used in humans for intestinal worms) and albendazole. Fenbendazole has been in use since the 1970s, has an excellent safety profile in animals, and is inexpensive and widely available. None of these facts would have made it newsworthy — until Joe Tippens.

The Preclinical Evidence: What Laboratory Studies Show. The preclinical evidence for fenbendazole's anticancer activity is more substantial than most people realize. A 2018 study published in Scientific Reports by Dogra et al. found that fenbendazole exhibited potent anticancer activity against human non-small cell lung cancer cells through multiple mechanisms: disruption of microtubule polymerization (preventing cell division), activation of the p53 tumor suppressor pathway, and inhibition of glucose uptake by downregulating GLUT transporters — effectively starving cancer cells of their primary fuel.

A 2020 study in Oncotarget found that fenbendazole inhibited the growth of colorectal cancer cells and sensitized them to radiation therapy. A 2021 study in Cancers demonstrated fenbendazole's activity against glioblastoma cells. Multiple studies have shown synergistic effects when fenbendazole is combined with other agents — particularly vitamin E succinate (as in the Tippens protocol), curcumin, and berberine.

The Tippens Protocol

Joe Tippens' protocol, as described in his blog and book, consisted of: fenbendazole (222 mg of Panacur C, a dog dewormer, three days on, four days off), vitamin E succinate (800 IU daily), curcumin (600 mg daily), and CBD oil. The three-days-on, four-days-off cycling was based on the standard veterinary dosing schedule for fenbendazole in dogs. Whether this cycling is necessary or optimal for anticancer effects in humans is unknown.

The Korean Phenomenon

Following Tippens' story going viral in South Korea in 2019, fenbendazole became a national phenomenon. Korean oncologists reported a surge in patients self-medicating with fenbendazole, and several Korean research groups began investigating its anticancer properties. A 2020 survey of Korean cancer patients found that 8.5% had used fenbendazole. Korean researchers have published several preclinical studies and are conducting observational studies of patients using fenbendazole.

Critical Limitations. The absence of clinical trial data remains the fundamental limitation. Preclinical activity — even robust, multi-mechanism preclinical activity — does not reliably predict clinical efficacy. The history of oncology is littered with compounds that killed cancer cells in vitro and in animal models but failed in human trials. Fenbendazole's bioavailability in humans is poorly characterized. The optimal dose, schedule, and combination partners for any potential anticancer effect are completely unknown.

⚕️ Disclaimer: Fenbendazole is not approved for human use as a cancer treatment. Using veterinary medications carries risks including unknown dosing, contamination, and drug interactions. The preclinical evidence, while intriguing, does not constitute proof of clinical efficacy. Anyone considering fenbendazole should do so only under physician supervision and should not discontinue conventional cancer treatment. This article is for educational purposes only.

Personalised plan

Healthy Aging Plan

Build a personalised plan for long-term health and prevention.

Get your personalised plan

Seen a claim you want to verify?

The Claim Decoder grades the evidence behind any natural health claim — A to F, with sources.

A— Strong RCTsB— Good evidenceC— Mixed studiesD— Weak evidenceF— No human data

Suggested from this article:

"High-dose vitamin C can treat cancer"

Prompted by: Fenbendazole & Cancer: A Deep Dive into the Evidence